UY30749A1 - Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada - Google Patents

Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada

Info

Publication number
UY30749A1
UY30749A1 UY30749A UY30749A UY30749A1 UY 30749 A1 UY30749 A1 UY 30749A1 UY 30749 A UY30749 A UY 30749A UY 30749 A UY30749 A UY 30749A UY 30749 A1 UY30749 A1 UY 30749A1
Authority
UY
Uruguay
Prior art keywords
fgf
biological activity
improved biological
fusiones
receiver
Prior art date
Application number
UY30749A
Other languages
English (en)
Inventor
Blanche Francis
Nesbit Mark
Cameron Beatrice
Sordello Sylvie
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of UY30749A1 publication Critical patent/UY30749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion se refiere a fusiones Fc con receptor para FGF soluble, modificadas, que comprenden una fusion de un fragmento o dominio solubles de la parte de receptor para FGF (porcion que establece el objetivo o fijadora) con una region Fc de una parte de inmunoglobulina (porcion con funcion efectora), que tienen actividad biologica mejorada, que incluye actividades de ADCC/CDC, a composiciones que las contienen, y a método de producir dichas moléculas de fusion Fc con receptor para FGF soluble modificadas.
UY30749A 2006-11-28 2007-11-29 Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada UY30749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28

Publications (1)

Publication Number Publication Date
UY30749A1 true UY30749A1 (es) 2008-07-03

Family

ID=37908084

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30749A UY30749A1 (es) 2006-11-28 2007-11-29 Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada

Country Status (5)

Country Link
CN (1) CN101589145B (es)
DO (1) DOP2009000115A (es)
ES (1) ES2366160T3 (es)
UY (1) UY30749A1 (es)
ZA (1) ZA200903134B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5945277B2 (ja) * 2010-11-15 2016-07-05 ファイブ プライム セラピューティックス インコーポレイテッド Ｆｇｆｒ１細胞外ドメイン併用療法
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
WO2014018673A2 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
CN116327924A (zh) * 2015-11-23 2023-06-27 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Also Published As

Publication number Publication date
ES2366160T3 (es) 2011-10-17
DOP2009000115A (es) 2010-02-15
CN101589145B (zh) 2013-11-13
CN101589145A (zh) 2009-11-25
ZA200903134B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
ECSP099361A (es) FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON
PE20081478A1 (es) Anticuerpos cd44
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
EA201170443A1 (ru) Связывающие множество мишеней белки, обладающие антагонистическими свойствами по отношению к cd86
PE20121561A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
ATE554105T1 (de) Veränderte antikörper
WO2010036969A3 (en) Genetic markers for assessing risk of developing schizophrenia
UY30749A1 (es) Fusiones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
DK2073842T3 (da) Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer.
WO2011091078A3 (en) Antibody fc variants with enhanced complement activity
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
GB2455449A (en) Activatable binding polypeptides and methods of indentifcation and use thereof
WO2008002472A3 (en) Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
WO2006133104A3 (en) Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2007120766A3 (en) Erythropoietin receptor agonists
AR093671A1 (es) Anticuerpos monoclonales contra una proteina activada c (apc)
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
CY1110441T1 (el) Μεθοδος για τον καθορισμο μιας μη-ανοσοσφαιρινικης πρωτεϊνης η οποια περιλαμβανει μια ανοσοσφαιρινη-ομοια (ig-ομοια) περιοχη

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140724